CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company ...

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $6.6 million in its fiscal second quarter. VIENNA, Va., April 23, 2025--CEL-SCI to file for Regulatory Approval of Multikine ...

Abstract: The use of pretrained backbones with fine-tuning has shown success for 2D vision and natural language processing tasks, with advantages over task-specific networks. In this paper, we ...

Abstract: Denoising diffusion models have demonstrated tremendous success in modeling data distributions and synthesizing high-quality samples. In the 2D image domain, they have become the ...

See CEL-SCI Corporation (CVM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

As of 2:16:49 p.m. EDT. Market Open.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

SEC Filings provided by EDGAR Online, Inc.

This data feed is not available at this time.

This impact will be seen in our chained volume measures (CVM) and implied deflator (IDEF) series. We do not plan any changes to the publication timetable for monthly UK trade and will continue to use ...